EMA Application withdrawn: Jesduvroq (daprodustat) — GlaxoSmithKline Trading Services Limited

View source ↗

Summary

The EMA has withdrawn the marketing authorization application for Jesduvroq (daprodustat) by GlaxoSmithKline Trading Services Limited.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Renal Insufficiency

Drugs mentioned

• JESDUVROQ (DAPRODUSTAT)

Snippet

Status: Application withdrawn. Therapeutic area: Renal Insufficiency, Chronic;Anemia. MAH: GlaxoSmithKline Trading Services Limited